Aeterna Zentaris deal

Aeterna Zentaris granted an undisclosed, privately held German life sciences company a 12-month option to license exclusive, worldwide rights to develop and commercialize Aeterna’s live, recombinant, oral, allogeneic tumor vaccine technology, including AEZS-120. Preclinical drug candidate AEZS-120 is a live, recombinant Salmonella typhi Ty21a-based oral vaccine expressing prostate-specific antigen ( KLK3; PSA) fused to the B subunit of cholera toxin. ...